Compass Therapeutics, Inc.
CMPX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001738021
In the last 90 days, Compass Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $363.4M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Compass Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 82 | 1 | 79 | −2 |
| Shares | 92.9M | 6.61M | 92.2M | +5.94M (+6.9%) |
| Value | $93.4M | $6.61M | $169.6M | +$82.8M (+95.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Compass Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 6,820,452 | $12.5M | 0.00% |
| Tang Capital Management LLC | 1,812,995 | $3.34M | 0.24% |
| Cantor Fitzgerald, L. P. | 180,000 | $331.2K | 0.03% |
| Manufacturers Life Insurance Company, The | 42,671 | $78.5K | 0.00% |
| XTX Topco Ltd | 20,221 | $37.2K | 0.00% |
| Intech Investment Management LLC | 16,292 | $30.0K | 0.00% |
| Financial Advisory Corp | 13,495 | $25.0K | 0.01% |
| North Star Investment Management Corp. | 12,500 | $23.0K | 0.00% |
| Bleakley Financial Group, LLC | 11,404 | $21.0K | 0.00% |
| Fortitude Family Office, LLC | 1,832 | $3.37K | 0.00% |
| Sterling Capital Management LLC | 324 | $596 | 0.00% |
| Capital Performance Advisors LLP | 172 | $316 | 0.00% |
Sold out (14)
Institutions that held Compass Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Cormorant Asset Management, LP | 2,030,823 | $2.03M |
| Wellington Management Group LLP | 243,650 | $243.7K |
| Pennant Investors, LP | 199,000 | $199.0K |
| Ground Swell Capital, LLC | 124,394 | $124.4K |
| HRT Financial LP | 122,038 | $122.0K |
| Squarepoint Ops LLC | 64,133 | $64.1K |
| Virtu Financial LLC | 51,233 | $51.0K |
| Cubist Systematic Strategies, LLC | 40,701 | $40.7K |
| TownSquare Capital, LLC | 19,195 | $19.2K |
| Principal Financial Group Inc | 10,000 | $10.0K |
| Point72 (DIFC) Ltd | 8,231 | $8.23K |
| Federated Hermes, Inc. | 3,592 | $3.59K |
| Hartford Financial Management Inc. | 1,000 | $1.00K |
| Point72 Asia (Singapore) Pte. Ltd. | 391 | $391 |
Not filed for Q3 2024 yet (1)
Institutions that held Compass Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 6,613,637 | $6.61M |